Persistent URL of this record https://hdl.handle.net/1887/3276429
Documents
In Collections
This item can be found in the following collections:
Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active Psoriatic Arthritis
- All authors
- McInnes, I.B.; Rahman, P.; Gottlieb, A.B.; Hsia, E.C.; Kollmeier, A.P.; Xu, X.L.; Jiang, Y.S.; Sheng, S.H.; Shawi, M.; Chakravarty, S.D.; Heijde, D. van der; Mease, P.J.
- Date
- 2022-02-07
- Journal
- Arthritis & Rheumatology
- Volume
- 74
- Issue
- 3
- Pages
- 475 - 485